Page 17 - சுயாதீனமான தகவல்கள் கண்காணிப்பு குழு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Medicago and GSK announce positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate

Medicago and GSK announce positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomThomas breuerNathalie landryAffairs at medicagoHealth canadaMelinda gates foundationData monitoring committeeQuebec cityExecutive vice presidentMedical affairsChief medical officerFast trackNorth americaLatin americaVir biotechnology

Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial

Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

South africaUnited kingdomSouth africanThomas triompheSanofi pasteurRoger connorNuclear defense under contractUs department of healthHuman servicesBiomedical advanced researchMelinda gates foundationData monitoring committeeDevelopment authorityExecutive vice presidentAssistant secretaryDefense joint program executive office

Formulation & packing of CanSino Bio start in Pakistan--China Economic Net

ISLAMABAD, May 8 (Gwadar Pro) - Pakistan has started the formulation and packing of China’s CanSino Bio vaccine at National Institute of Health (NIH) in Islamabad. Federal Minister Asad Umar confirmed the development in a tweet and said, “The first batch of bulk CanSino vaccine being processed at the National Institute of Health [at a] plant set up for this purpose last month. [A] Specially trained team [is] working on it.” The vaccine would be available for use by the end of May after going through “rigorous quality control checks,” he added. According to an official of NIH, the raw materials for the vaccine have been imported from China while a team of Chinese experts is present in Islamabad to help in the preparation of vaccines. “We have enough raw material to prepare up to 120,000 doses of Cansino,” the official added.

Asad umarCansino bioTahir aliLiao yifanDrug regulatory authority of pakistanNational institute of healthData monitoring committeeGwadar proNational instituteMinister asad umarIndependent data monitoring committeeRegulatory authorityஅசாத் உமர்கேன்சினோ உயிர்தாஹிர் அலிமருந்து ஒழுங்குமுறை அதிகாரம் ஆஃப் பாக்கிஸ்தான்

GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831

Press release content from Globe Newswire. The AP news staff was not involved in its creation. GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 . Vir Biotechnology, Inc.May 7, 2021 GMT – Rolling review will evaluate sotrovimab in adults and adolescents with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19 – – Review will support a formal Marketing Authorization Application – – GSK and Vir continue discussions with global regulators to make sotrovimab available to patients with COVID-19 – LONDON and SAN FRANCISCO, May 07, 2021 (GLOBE NEWSWIRE) GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the European Medicines Agency (EMA) has started a rolling review of data on sotrovimab (previously VIR-7831), an investigational dual-action SARS-CoV-2 monoclonal antibody, for the treatment of adults and adolescents (aged 12 years and o

United statesUnited kingdomCity ofUnited kingdom generalKathleen quinnJeff mclaughlinSimon steelSonya ghobrialEli lillyMick readeyLyndsay meyerTim foleyJames dodwellKristen neeseVir biotechnology incNational health

AstraZeneca: ASTRAZENECA SECURES LICENSE EXTENSION AND EARLY NHS ENGLAND ACCESS TO TAGRISSO ? (osimertinib) FOR PATIENTS WITH COMPLETELY RESECTED EARLY-STAGE EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER

AstraZeneca: ASTRAZENECA SECURES LICENSE EXTENSION AND EARLY NHS ENGLAND ACCESS TO TAGRISSO - (osimertinib) FOR PATIENTS WITH COMPLETELY RESECTED EARLY-STAGE EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER 1 AstraZeneca, NHS England and NICE have reached an agreement to enable early access to osimertinib for patients with this type of cancer, while NICE undertakes its appraisal. Patients with early-stage lung cancer are treated with the intention of cure; however, many relapse because treatment is limited to surgery and adjuvant chemotherapy. 2 Unprecedented clinical trial data show that osimertinib, the first approved targeted oral therapy in this setting, can reduce the risk of disease recurrence or death by 80% in patients with early-stage (IB-IIIA) EGFR mutation-positive NSCLC versus placebo.

United kingdomUnited statesGreat britainAlex larkinsonKarun krishnaCarles escriuLe chevalierCollaborative groupNational lung cancer auditClatterbridge cancer centreArch pathol labRoyal college of physiciansData monitoring committeeRegulatory agencyNational institute for healthCancer research united kingdom